Abstract
Background Alzheimer’s disease (AD) is the most common adult form of dementia.1 It is an age-associated neurodegenerative disorder pathologically characterized by the abnormal accumulation of intracellular neurofibrillary tangles and extra cellular amyloid plaques in selected brain regions. Donepezil is a cholinesterase inhibitor currently being used in the treatment of Alzheimer’s disease is metabolized via CYP2D6 enzymes. The present study was undertaken to investigate CYP2D6*4 polymorphism on the serum concentration of Donepezil with responders and non-responders to Alzheimer’s patients.
Highlights
Alzheimer’s disease (AD) is the most common adult form of dementia.1 It is an age-associated neurodegenerative disorder pathologically characterized by the abnormal accumulation of intracellular neurofibrillary tangles and extra cellular amyloid plaques in selected brain regions
Our finding suggest that the CYP2D6 *4 genetic polymorphism may be associated with the individual differences in donezepil metabolism
ResultsThe CYP2D6*4 Polymorphism was seen to be in Hardy - Weinberg equilibrium and showed significant allelic association and genotypic association between responders and non-responders of donezepil
Summary
Association of CYP2D6*4 genetic polymorphism on the metabolism of Donepezil with Alzheimer’s disease in Indian population. From 1st International Congress on Neurobiology and Clinical Psychopharmacology and European Psychiatric Association Conference on Treatment Guidance Thessaloniki, Greece. 19-22 November 2009
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
